Cargando…

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

SIMPLE SUMMARY: Several strategies have demonstrated the ability to improve the survival of patients with both metastatic and nonmetastatic prostate cancer. The old backbone of androgen-deprivation monotherapy has been disrupted in the hormone-sensitive setting, and several options have been introdu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattrini, Carlo, España, Rodrigo, Mennitto, Alessia, Bersanelli, Melissa, Castro, Elena, Olmos, David, Lorente, David, Gennari, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467385/
https://www.ncbi.nlm.nih.gov/pubmed/34572748
http://dx.doi.org/10.3390/cancers13184522
_version_ 1784573384184561664
author Cattrini, Carlo
España, Rodrigo
Mennitto, Alessia
Bersanelli, Melissa
Castro, Elena
Olmos, David
Lorente, David
Gennari, Alessandra
author_facet Cattrini, Carlo
España, Rodrigo
Mennitto, Alessia
Bersanelli, Melissa
Castro, Elena
Olmos, David
Lorente, David
Gennari, Alessandra
author_sort Cattrini, Carlo
collection PubMed
description SIMPLE SUMMARY: Several strategies have demonstrated the ability to improve the survival of patients with both metastatic and nonmetastatic prostate cancer. The old backbone of androgen-deprivation monotherapy has been disrupted in the hormone-sensitive setting, and several options have been introduced for the management of the castration-resistant disease. However, no optimal sequencing is still defined, and few randomized comparisons are currently available to identify the approach that maximizes the long-term benefit for these patients. This comprehensive review aims at resuming the current evidence on this topic to help physicians during the treatment choice for patients with advanced prostate cancer. ABSTRACT: The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177–PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).
format Online
Article
Text
id pubmed-8467385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84673852021-09-27 Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer Cattrini, Carlo España, Rodrigo Mennitto, Alessia Bersanelli, Melissa Castro, Elena Olmos, David Lorente, David Gennari, Alessandra Cancers (Basel) Review SIMPLE SUMMARY: Several strategies have demonstrated the ability to improve the survival of patients with both metastatic and nonmetastatic prostate cancer. The old backbone of androgen-deprivation monotherapy has been disrupted in the hormone-sensitive setting, and several options have been introduced for the management of the castration-resistant disease. However, no optimal sequencing is still defined, and few randomized comparisons are currently available to identify the approach that maximizes the long-term benefit for these patients. This comprehensive review aims at resuming the current evidence on this topic to help physicians during the treatment choice for patients with advanced prostate cancer. ABSTRACT: The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177–PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN). MDPI 2021-09-08 /pmc/articles/PMC8467385/ /pubmed/34572748 http://dx.doi.org/10.3390/cancers13184522 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cattrini, Carlo
España, Rodrigo
Mennitto, Alessia
Bersanelli, Melissa
Castro, Elena
Olmos, David
Lorente, David
Gennari, Alessandra
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
title Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
title_full Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
title_fullStr Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
title_full_unstemmed Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
title_short Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
title_sort optimal sequencing and predictive biomarkers in patients with advanced prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467385/
https://www.ncbi.nlm.nih.gov/pubmed/34572748
http://dx.doi.org/10.3390/cancers13184522
work_keys_str_mv AT cattrinicarlo optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT espanarodrigo optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT mennittoalessia optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT bersanellimelissa optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT castroelena optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT olmosdavid optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT lorentedavid optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer
AT gennarialessandra optimalsequencingandpredictivebiomarkersinpatientswithadvancedprostatecancer